医学
彭布罗利珠单抗
卡铂
危险系数
吉西他滨
肿瘤科
化疗
内科学
杜瓦卢马布
癌症
顺铂
置信区间
免疫疗法
作者
Thomas Powles,Begoña P. Valderrama,Shilpa Gupta,Jens Bedke,Eiji Kikuchi,Jean Hoffman‐Censits,Gopa Iyer,Christof Vulsteke,Se Hoon Park,Sang Joon Shin,Daniel Castellano,Giuseppe Fornarini,Jian‐Ri Li,Mahmut Gümüş,Nataliya Mar,Yohann Loriot,Aude Fléchon,Ignacio Durán,Alexandra Drakaki,Sujata Narayanan
标识
DOI：10.1056/nejmoa2312117
摘要
Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
浮游
asdfzxcv
Criminology34
无极微光
ceeray23
进击的PhD
王丽娟
smottom
BowieHuang
香蕉诗蕊
yznfly
小青椒
Jared
wy.he
个性的荆
Mic
专注的问寒
归尘
Twonej
三岁
niNe3YUE
iNk
竹筏过海
wxyshare
皖公网安备34019202002308
